These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34192548)

  • 21. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
    Ahn K; O YM; Ji YG; Cho HJ; Lee DH
    Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
    Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
    Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
    PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSRP2 suppresses colorectal cancer progression
    Chen L; Long X; Duan S; Liu X; Chen J; Lan J; Liu X; Huang W; Geng J; Zhou J
    Theranostics; 2020; 10(24):11063-11079. PubMed ID: 33042270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors.
    Chen C; Jiang YP; You I; Gray NS; Lin RZ
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
    Sato K; Hikita H; Myojin Y; Fukumoto K; Murai K; Sakane S; Tamura T; Yamai T; Nozaki Y; Yoshioka T; Kodama T; Shigekawa M; Sakamori R; Tatsumi T; Takehara T
    PLoS One; 2020; 15(7):e0235573. PubMed ID: 32609742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
    Klomp JA; Klomp JE; Stalnecker CA; Bryant KL; Edwards AC; Drizyte-Miller K; Hibshman PS; Diehl JN; Lee YS; Morales AJ; Taylor KE; Peng S; Tran NL; Herring LE; Prevatte AW; Barker NK; Hover LD; Hallin J; Sorokin A; Kanikarla PM; Chowdhury S; Coker O; Lee HM; Goodwin CM; Gautam P; Olson P; Christensen JG; Shen JP; Kopetz S; Graves LM; Lim KH; Wang-Gillam A; Wennerberg K; Cox AD; Der CJ
    Science; 2024 Jun; 384(6700):eadk0775. PubMed ID: 38843331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
    Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA
    Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
    Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
    Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
    Lewis CS; Voelkel-Johnson C; Smith CD
    Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
    Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
    Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.